Status:
WITHDRAWN
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
Lead Sponsor:
Northwell Health
Collaborating Sponsors:
Medical College of Wisconsin
Conditions:
Focal Segmental Glomerulosclerosis
Eligibility:
All Genders
2-60 years
Phase:
PHASE1
Brief Summary
This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability...
Detailed Description
Patients with resistant FSGS have persistent proteinuria and a high risk of progression to end stage kidney disease (ESKD). A circulating factor that increases glomerular permeability to albumin (Palb...
Eligibility Criteria
Inclusion
- Primary FSGS
- CKD Stage 5
- Resistance to steroids and another immunosuppressive medication
Exclusion
- Secondary FSGS
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00816504
Start Date
December 1 2008
End Date
December 1 2009
Last Update
September 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226